English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background The somatically related antibodies, PG9 and PG16, neutralize 70-80% of HIV-1 isolates and bind a glycosylated epitope in the V1/V2 domain of HIV-1 gp120. Mutations in V1/V2, and sometimes V3 depending on the HIV-1 strain, affect neutralization and a glycan on Asn160 is required for neutralization. Both antibodies also preferentially bind the native trimer over monomeric gp120, especially PG16. The structure of PG9 in complex with its epitope, a scaffolded V1/V2 from HIV-1 strain ZM109, was recently solved and showed that PG9 targets a site of vulnerability comprising 2 glycans and a b-strand.

Structural comparison of somatically related PG9 and PG16 in complex with their epitope reveals differences in glycan recognition